Cited 9 times in
Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상길 | - |
dc.contributor.author | 박찬혁 | - |
dc.date.accessioned | 2015-12-28T10:52:33Z | - |
dc.date.available | 2015-12-28T10:52:33Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138215 | - |
dc.description.abstract | BACKGROUND/AIMS: DA-9701 (Motilitone) is a new prokinetic agent formulated with Corydalis Tuber and Pharbitis Seed. We assessed the efficacy of DA-9701 in symptomatic patients with minimal change esophagitis. METHODS: Patients with minimal change esophagitis presenting with reflux or dyspeptic symptoms were randomly assigned to receive either DA-9701 30 mg or placebo t.i.d. (means 3 times a day). After 4 weeks of treatment, the primary efficacy end point determined by changes of the Nepean dyspepsia index questionnaire-Korean version (NDI-K) symptom scores, was analyzed. RESULTS: Forty-two and 39 patients were assigned to the treatment and control groups, respectively. After 4 weeks, NDI-K symptom scores were reduced from 35.4 to 13.5 (P < 0.001) and from 43.0 to 27.7 (P < 0.001) in the treatment and the control groups, respectively. However, changes in the symptom scores did not differ between the 2 groups (P = 0.741). Although the quality of life scores were significantly improved after 4 weeks in both groups, changes in the quality of life score between the baseline value and that at 4 weeks did not differ between the 2 groups. The reflux symptom score was significantly improved in the treatment group compared to the placebo group in patients aged 65 years or older (P = 0.035). CONCLUSIONS: Although NDI-K symptom scores and quality of life scores were improved after 4 weeks of treatment compared with baseline values in patients with minimal change esophagitis, DA-9701 did not improve the symptom scores or quality of life scores compared with the placebo. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 338~346 | - |
dc.relation.isPartOf | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chan Hyuk Park | - |
dc.contributor.googleauthor | Hyun Soo Kim | - |
dc.contributor.googleauthor | Sang Kil Lee | - |
dc.identifier.doi | 10.5056/jnm14019 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02812 | - |
dc.contributor.localId | A01711 | - |
dc.relation.journalcode | J01623 | - |
dc.identifier.eissn | 2093-0887 | - |
dc.identifier.pmid | 24953714 | - |
dc.subject.keyword | DA-9701, Minimal change esophagitis, Motilitone, Non-erosive reflux disease | - |
dc.contributor.alternativeName | Lee, Sang Kil | - |
dc.contributor.alternativeName | Park, Chan Hyuk | - |
dc.contributor.affiliatedAuthor | Lee, Sang Kil | - |
dc.contributor.affiliatedAuthor | Park, Chan Hyuk | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 338 | - |
dc.citation.endPage | 346 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, Vol.20(3) : 338-346, 2014 | - |
dc.identifier.rimsid | 47226 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.